Extended recombinant bacterial ghost system

Controlled expression of cloned PhiX174 gene E in Gram-negative bacteria results in lysis of the bacteria by formation of an E-specific transmembrane tunnel structure built through the cell envelope complex. Bacterial ghosts from a variety of bacteria are used as non-living candidate vaccines. In th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biotechnology 1999-08, Vol.73 (2), p.261-273
Hauptverfasser: Lubitz, W., Witte, A., Eko, F.O., Kamal, M., Jechlinger, W., Brand, E., Marchart, J., Haidinger, W., Huter, V., Felnerova, D., Stralis-Alves, N., Lechleitner, S., Melzer, H., Szostak, M.P., Resch, S., Mader, H., Kuen, B., Mayr, B., Mayrhofer, P., Geretschläger, R., Haslberger, A., Hensel, A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 273
container_issue 2
container_start_page 261
container_title Journal of biotechnology
container_volume 73
creator Lubitz, W.
Witte, A.
Eko, F.O.
Kamal, M.
Jechlinger, W.
Brand, E.
Marchart, J.
Haidinger, W.
Huter, V.
Felnerova, D.
Stralis-Alves, N.
Lechleitner, S.
Melzer, H.
Szostak, M.P.
Resch, S.
Mader, H.
Kuen, B.
Mayr, B.
Mayrhofer, P.
Geretschläger, R.
Haslberger, A.
Hensel, A.
description Controlled expression of cloned PhiX174 gene E in Gram-negative bacteria results in lysis of the bacteria by formation of an E-specific transmembrane tunnel structure built through the cell envelope complex. Bacterial ghosts from a variety of bacteria are used as non-living candidate vaccines. In the recombinant ghost system, foreign proteins are attached on the inside of the inner membrane as fusions with specific anchor sequences. Ghosts have a sealed periplasmic space and the export of proteins into this space vastly extends the capacity of ghosts or recombinant ghosts to function as carriers of foreign antigens. In addition, S-layer proteins forming shell-like self assembly structures can be expressed in candidate vaccine strains prior to E-mediated lysis. Such recombinant S-layer proteins carrying foreign epitopes further extend the possibilities of ghosts as carriers of foreign epitopes. As ghosts have inherent adjuvant properties, they can be used as adjuvants in combination with subunit vaccines. Subunits or other ligands can also be coupled to matrixes like dextran which are used to fill the internal lumen of ghosts. Oral, aerogenic or parenteral immunization of experimental animals with recombinant ghosts induced specific humoral and cellular immune responses against bacterial and target components including protective mucosal immunity. The most relevant advantage of recombinant bacterial ghosts as immunogens is that no inactivation procedures that denature relevant immunogenic determinants are employed in this production. This fact explains the superior quality of ghosts when compared to other inactivated vaccines. The endotoxic component of the outer membrane does not limit the use of ghosts as vaccine candidates but triggers the release of several potent immunoregulatory cytokines. As carriers, there is no limitation in the size of foreign antigens that can be inserted in the membrane and the capacity of all spaces including the membranes, periplasma and internal lumen of the ghosts can be fully utilized. This extended recombinant ghost system represents a new stategy for adjuvant free combination vaccines.
doi_str_mv 10.1016/S0168-1656(99)00144-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70034197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168165699001443</els_id><sourcerecordid>70034197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-a1a4b2dc2761de55f9a785c47a18320303cbb2552bbdd1abaf9787fa1e3b6eae3</originalsourceid><addsrcrecordid>eNqF0E1LHTEUgOEgil5tf4JyF1IsMm3OZDJJVkUutgpCF23X4SQ5o5H50GSu6L937gfanZtkkeck4WXsGPg34FB__zMtuoBa1mfGfOUcqqoQO2wGWomi0rXYZbM3csAOc77nnFdGwj47AD4JI-SMnV8-j9QHCvNEfuhc7LEf5w79SCliO7-9G_I4zy95pO4T22uwzfR5ux-xfz8v_y6uipvfv64XFzeFr5QYCwSsXBl8qWoIJGVjUGk5nSFoUXLBhXeulLJ0LgRAh41RWjUIJFxNSOKIfdnc-5CGxyXl0XYxe2pb7GlYZqs4FxUY9SEEJSqhy3KCcgN9GnJO1NiHFDtMLxa4XeW065x21coaY9c5rZjmTrYPLF1H4b-pTb8JnG4BZo9tk7D3Mb87I7WGFfuxYTRle4qUbPaRek8hTtlHG4b4wU9eAU30kL4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17343822</pqid></control><display><type>article</type><title>Extended recombinant bacterial ghost system</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Lubitz, W. ; Witte, A. ; Eko, F.O. ; Kamal, M. ; Jechlinger, W. ; Brand, E. ; Marchart, J. ; Haidinger, W. ; Huter, V. ; Felnerova, D. ; Stralis-Alves, N. ; Lechleitner, S. ; Melzer, H. ; Szostak, M.P. ; Resch, S. ; Mader, H. ; Kuen, B. ; Mayr, B. ; Mayrhofer, P. ; Geretschläger, R. ; Haslberger, A. ; Hensel, A.</creator><creatorcontrib>Lubitz, W. ; Witte, A. ; Eko, F.O. ; Kamal, M. ; Jechlinger, W. ; Brand, E. ; Marchart, J. ; Haidinger, W. ; Huter, V. ; Felnerova, D. ; Stralis-Alves, N. ; Lechleitner, S. ; Melzer, H. ; Szostak, M.P. ; Resch, S. ; Mader, H. ; Kuen, B. ; Mayr, B. ; Mayrhofer, P. ; Geretschläger, R. ; Haslberger, A. ; Hensel, A.</creatorcontrib><description>Controlled expression of cloned PhiX174 gene E in Gram-negative bacteria results in lysis of the bacteria by formation of an E-specific transmembrane tunnel structure built through the cell envelope complex. Bacterial ghosts from a variety of bacteria are used as non-living candidate vaccines. In the recombinant ghost system, foreign proteins are attached on the inside of the inner membrane as fusions with specific anchor sequences. Ghosts have a sealed periplasmic space and the export of proteins into this space vastly extends the capacity of ghosts or recombinant ghosts to function as carriers of foreign antigens. In addition, S-layer proteins forming shell-like self assembly structures can be expressed in candidate vaccine strains prior to E-mediated lysis. Such recombinant S-layer proteins carrying foreign epitopes further extend the possibilities of ghosts as carriers of foreign epitopes. As ghosts have inherent adjuvant properties, they can be used as adjuvants in combination with subunit vaccines. Subunits or other ligands can also be coupled to matrixes like dextran which are used to fill the internal lumen of ghosts. Oral, aerogenic or parenteral immunization of experimental animals with recombinant ghosts induced specific humoral and cellular immune responses against bacterial and target components including protective mucosal immunity. The most relevant advantage of recombinant bacterial ghosts as immunogens is that no inactivation procedures that denature relevant immunogenic determinants are employed in this production. This fact explains the superior quality of ghosts when compared to other inactivated vaccines. The endotoxic component of the outer membrane does not limit the use of ghosts as vaccine candidates but triggers the release of several potent immunoregulatory cytokines. As carriers, there is no limitation in the size of foreign antigens that can be inserted in the membrane and the capacity of all spaces including the membranes, periplasma and internal lumen of the ghosts can be fully utilized. This extended recombinant ghost system represents a new stategy for adjuvant free combination vaccines.</description><identifier>ISSN: 0168-1656</identifier><identifier>EISSN: 1873-4863</identifier><identifier>DOI: 10.1016/S0168-1656(99)00144-3</identifier><identifier>PMID: 10486935</identifier><identifier>CODEN: JBITD4</identifier><language>eng</language><publisher>Lausanne: Elsevier B.V</publisher><subject>Adjuvants ; Adjuvants, Immunologic - administration &amp; dosage ; Animals ; Antigens - administration &amp; dosage ; Bacterial ghost ; Bacteriophage phi X 174 - genetics ; Biological and medical sciences ; Biotechnology ; Cell Membrane - genetics ; Chimera - genetics ; Combination vaccines ; Delivery system ; Drug Carriers ; Fundamental and applied biological sciences. Psychology ; Gene Expression ; Genes, Viral ; Gram-Negative Bacteria - genetics ; Gram-Negative Bacteria - immunology ; Health. Pharmaceutical industry ; Humans ; Industrial applications and implications. Economical aspects ; Inflammation Mediators - metabolism ; Production of active biomolecules ; Recombination, Genetic ; Vaccines, Combined - administration &amp; dosage ; Vaccines, Synthetic - administration &amp; dosage ; Vaccins</subject><ispartof>Journal of biotechnology, 1999-08, Vol.73 (2), p.261-273</ispartof><rights>1999 Elsevier Science B.V.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-a1a4b2dc2761de55f9a785c47a18320303cbb2552bbdd1abaf9787fa1e3b6eae3</citedby><cites>FETCH-LOGICAL-c473t-a1a4b2dc2761de55f9a785c47a18320303cbb2552bbdd1abaf9787fa1e3b6eae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0168-1656(99)00144-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1958815$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10486935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lubitz, W.</creatorcontrib><creatorcontrib>Witte, A.</creatorcontrib><creatorcontrib>Eko, F.O.</creatorcontrib><creatorcontrib>Kamal, M.</creatorcontrib><creatorcontrib>Jechlinger, W.</creatorcontrib><creatorcontrib>Brand, E.</creatorcontrib><creatorcontrib>Marchart, J.</creatorcontrib><creatorcontrib>Haidinger, W.</creatorcontrib><creatorcontrib>Huter, V.</creatorcontrib><creatorcontrib>Felnerova, D.</creatorcontrib><creatorcontrib>Stralis-Alves, N.</creatorcontrib><creatorcontrib>Lechleitner, S.</creatorcontrib><creatorcontrib>Melzer, H.</creatorcontrib><creatorcontrib>Szostak, M.P.</creatorcontrib><creatorcontrib>Resch, S.</creatorcontrib><creatorcontrib>Mader, H.</creatorcontrib><creatorcontrib>Kuen, B.</creatorcontrib><creatorcontrib>Mayr, B.</creatorcontrib><creatorcontrib>Mayrhofer, P.</creatorcontrib><creatorcontrib>Geretschläger, R.</creatorcontrib><creatorcontrib>Haslberger, A.</creatorcontrib><creatorcontrib>Hensel, A.</creatorcontrib><title>Extended recombinant bacterial ghost system</title><title>Journal of biotechnology</title><addtitle>J Biotechnol</addtitle><description>Controlled expression of cloned PhiX174 gene E in Gram-negative bacteria results in lysis of the bacteria by formation of an E-specific transmembrane tunnel structure built through the cell envelope complex. Bacterial ghosts from a variety of bacteria are used as non-living candidate vaccines. In the recombinant ghost system, foreign proteins are attached on the inside of the inner membrane as fusions with specific anchor sequences. Ghosts have a sealed periplasmic space and the export of proteins into this space vastly extends the capacity of ghosts or recombinant ghosts to function as carriers of foreign antigens. In addition, S-layer proteins forming shell-like self assembly structures can be expressed in candidate vaccine strains prior to E-mediated lysis. Such recombinant S-layer proteins carrying foreign epitopes further extend the possibilities of ghosts as carriers of foreign epitopes. As ghosts have inherent adjuvant properties, they can be used as adjuvants in combination with subunit vaccines. Subunits or other ligands can also be coupled to matrixes like dextran which are used to fill the internal lumen of ghosts. Oral, aerogenic or parenteral immunization of experimental animals with recombinant ghosts induced specific humoral and cellular immune responses against bacterial and target components including protective mucosal immunity. The most relevant advantage of recombinant bacterial ghosts as immunogens is that no inactivation procedures that denature relevant immunogenic determinants are employed in this production. This fact explains the superior quality of ghosts when compared to other inactivated vaccines. The endotoxic component of the outer membrane does not limit the use of ghosts as vaccine candidates but triggers the release of several potent immunoregulatory cytokines. As carriers, there is no limitation in the size of foreign antigens that can be inserted in the membrane and the capacity of all spaces including the membranes, periplasma and internal lumen of the ghosts can be fully utilized. This extended recombinant ghost system represents a new stategy for adjuvant free combination vaccines.</description><subject>Adjuvants</subject><subject>Adjuvants, Immunologic - administration &amp; dosage</subject><subject>Animals</subject><subject>Antigens - administration &amp; dosage</subject><subject>Bacterial ghost</subject><subject>Bacteriophage phi X 174 - genetics</subject><subject>Biological and medical sciences</subject><subject>Biotechnology</subject><subject>Cell Membrane - genetics</subject><subject>Chimera - genetics</subject><subject>Combination vaccines</subject><subject>Delivery system</subject><subject>Drug Carriers</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene Expression</subject><subject>Genes, Viral</subject><subject>Gram-Negative Bacteria - genetics</subject><subject>Gram-Negative Bacteria - immunology</subject><subject>Health. Pharmaceutical industry</subject><subject>Humans</subject><subject>Industrial applications and implications. Economical aspects</subject><subject>Inflammation Mediators - metabolism</subject><subject>Production of active biomolecules</subject><subject>Recombination, Genetic</subject><subject>Vaccines, Combined - administration &amp; dosage</subject><subject>Vaccines, Synthetic - administration &amp; dosage</subject><subject>Vaccins</subject><issn>0168-1656</issn><issn>1873-4863</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0E1LHTEUgOEgil5tf4JyF1IsMm3OZDJJVkUutgpCF23X4SQ5o5H50GSu6L937gfanZtkkeck4WXsGPg34FB__zMtuoBa1mfGfOUcqqoQO2wGWomi0rXYZbM3csAOc77nnFdGwj47AD4JI-SMnV8-j9QHCvNEfuhc7LEf5w79SCliO7-9G_I4zy95pO4T22uwzfR5ux-xfz8v_y6uipvfv64XFzeFr5QYCwSsXBl8qWoIJGVjUGk5nSFoUXLBhXeulLJ0LgRAh41RWjUIJFxNSOKIfdnc-5CGxyXl0XYxe2pb7GlYZqs4FxUY9SEEJSqhy3KCcgN9GnJO1NiHFDtMLxa4XeW065x21coaY9c5rZjmTrYPLF1H4b-pTb8JnG4BZo9tk7D3Mb87I7WGFfuxYTRle4qUbPaRek8hTtlHG4b4wU9eAU30kL4</recordid><startdate>19990820</startdate><enddate>19990820</enddate><creator>Lubitz, W.</creator><creator>Witte, A.</creator><creator>Eko, F.O.</creator><creator>Kamal, M.</creator><creator>Jechlinger, W.</creator><creator>Brand, E.</creator><creator>Marchart, J.</creator><creator>Haidinger, W.</creator><creator>Huter, V.</creator><creator>Felnerova, D.</creator><creator>Stralis-Alves, N.</creator><creator>Lechleitner, S.</creator><creator>Melzer, H.</creator><creator>Szostak, M.P.</creator><creator>Resch, S.</creator><creator>Mader, H.</creator><creator>Kuen, B.</creator><creator>Mayr, B.</creator><creator>Mayrhofer, P.</creator><creator>Geretschläger, R.</creator><creator>Haslberger, A.</creator><creator>Hensel, A.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19990820</creationdate><title>Extended recombinant bacterial ghost system</title><author>Lubitz, W. ; Witte, A. ; Eko, F.O. ; Kamal, M. ; Jechlinger, W. ; Brand, E. ; Marchart, J. ; Haidinger, W. ; Huter, V. ; Felnerova, D. ; Stralis-Alves, N. ; Lechleitner, S. ; Melzer, H. ; Szostak, M.P. ; Resch, S. ; Mader, H. ; Kuen, B. ; Mayr, B. ; Mayrhofer, P. ; Geretschläger, R. ; Haslberger, A. ; Hensel, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-a1a4b2dc2761de55f9a785c47a18320303cbb2552bbdd1abaf9787fa1e3b6eae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adjuvants</topic><topic>Adjuvants, Immunologic - administration &amp; dosage</topic><topic>Animals</topic><topic>Antigens - administration &amp; dosage</topic><topic>Bacterial ghost</topic><topic>Bacteriophage phi X 174 - genetics</topic><topic>Biological and medical sciences</topic><topic>Biotechnology</topic><topic>Cell Membrane - genetics</topic><topic>Chimera - genetics</topic><topic>Combination vaccines</topic><topic>Delivery system</topic><topic>Drug Carriers</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene Expression</topic><topic>Genes, Viral</topic><topic>Gram-Negative Bacteria - genetics</topic><topic>Gram-Negative Bacteria - immunology</topic><topic>Health. Pharmaceutical industry</topic><topic>Humans</topic><topic>Industrial applications and implications. Economical aspects</topic><topic>Inflammation Mediators - metabolism</topic><topic>Production of active biomolecules</topic><topic>Recombination, Genetic</topic><topic>Vaccines, Combined - administration &amp; dosage</topic><topic>Vaccines, Synthetic - administration &amp; dosage</topic><topic>Vaccins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lubitz, W.</creatorcontrib><creatorcontrib>Witte, A.</creatorcontrib><creatorcontrib>Eko, F.O.</creatorcontrib><creatorcontrib>Kamal, M.</creatorcontrib><creatorcontrib>Jechlinger, W.</creatorcontrib><creatorcontrib>Brand, E.</creatorcontrib><creatorcontrib>Marchart, J.</creatorcontrib><creatorcontrib>Haidinger, W.</creatorcontrib><creatorcontrib>Huter, V.</creatorcontrib><creatorcontrib>Felnerova, D.</creatorcontrib><creatorcontrib>Stralis-Alves, N.</creatorcontrib><creatorcontrib>Lechleitner, S.</creatorcontrib><creatorcontrib>Melzer, H.</creatorcontrib><creatorcontrib>Szostak, M.P.</creatorcontrib><creatorcontrib>Resch, S.</creatorcontrib><creatorcontrib>Mader, H.</creatorcontrib><creatorcontrib>Kuen, B.</creatorcontrib><creatorcontrib>Mayr, B.</creatorcontrib><creatorcontrib>Mayrhofer, P.</creatorcontrib><creatorcontrib>Geretschläger, R.</creatorcontrib><creatorcontrib>Haslberger, A.</creatorcontrib><creatorcontrib>Hensel, A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lubitz, W.</au><au>Witte, A.</au><au>Eko, F.O.</au><au>Kamal, M.</au><au>Jechlinger, W.</au><au>Brand, E.</au><au>Marchart, J.</au><au>Haidinger, W.</au><au>Huter, V.</au><au>Felnerova, D.</au><au>Stralis-Alves, N.</au><au>Lechleitner, S.</au><au>Melzer, H.</au><au>Szostak, M.P.</au><au>Resch, S.</au><au>Mader, H.</au><au>Kuen, B.</au><au>Mayr, B.</au><au>Mayrhofer, P.</au><au>Geretschläger, R.</au><au>Haslberger, A.</au><au>Hensel, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extended recombinant bacterial ghost system</atitle><jtitle>Journal of biotechnology</jtitle><addtitle>J Biotechnol</addtitle><date>1999-08-20</date><risdate>1999</risdate><volume>73</volume><issue>2</issue><spage>261</spage><epage>273</epage><pages>261-273</pages><issn>0168-1656</issn><eissn>1873-4863</eissn><coden>JBITD4</coden><abstract>Controlled expression of cloned PhiX174 gene E in Gram-negative bacteria results in lysis of the bacteria by formation of an E-specific transmembrane tunnel structure built through the cell envelope complex. Bacterial ghosts from a variety of bacteria are used as non-living candidate vaccines. In the recombinant ghost system, foreign proteins are attached on the inside of the inner membrane as fusions with specific anchor sequences. Ghosts have a sealed periplasmic space and the export of proteins into this space vastly extends the capacity of ghosts or recombinant ghosts to function as carriers of foreign antigens. In addition, S-layer proteins forming shell-like self assembly structures can be expressed in candidate vaccine strains prior to E-mediated lysis. Such recombinant S-layer proteins carrying foreign epitopes further extend the possibilities of ghosts as carriers of foreign epitopes. As ghosts have inherent adjuvant properties, they can be used as adjuvants in combination with subunit vaccines. Subunits or other ligands can also be coupled to matrixes like dextran which are used to fill the internal lumen of ghosts. Oral, aerogenic or parenteral immunization of experimental animals with recombinant ghosts induced specific humoral and cellular immune responses against bacterial and target components including protective mucosal immunity. The most relevant advantage of recombinant bacterial ghosts as immunogens is that no inactivation procedures that denature relevant immunogenic determinants are employed in this production. This fact explains the superior quality of ghosts when compared to other inactivated vaccines. The endotoxic component of the outer membrane does not limit the use of ghosts as vaccine candidates but triggers the release of several potent immunoregulatory cytokines. As carriers, there is no limitation in the size of foreign antigens that can be inserted in the membrane and the capacity of all spaces including the membranes, periplasma and internal lumen of the ghosts can be fully utilized. This extended recombinant ghost system represents a new stategy for adjuvant free combination vaccines.</abstract><cop>Lausanne</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>10486935</pmid><doi>10.1016/S0168-1656(99)00144-3</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-1656
ispartof Journal of biotechnology, 1999-08, Vol.73 (2), p.261-273
issn 0168-1656
1873-4863
language eng
recordid cdi_proquest_miscellaneous_70034197
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adjuvants
Adjuvants, Immunologic - administration & dosage
Animals
Antigens - administration & dosage
Bacterial ghost
Bacteriophage phi X 174 - genetics
Biological and medical sciences
Biotechnology
Cell Membrane - genetics
Chimera - genetics
Combination vaccines
Delivery system
Drug Carriers
Fundamental and applied biological sciences. Psychology
Gene Expression
Genes, Viral
Gram-Negative Bacteria - genetics
Gram-Negative Bacteria - immunology
Health. Pharmaceutical industry
Humans
Industrial applications and implications. Economical aspects
Inflammation Mediators - metabolism
Production of active biomolecules
Recombination, Genetic
Vaccines, Combined - administration & dosage
Vaccines, Synthetic - administration & dosage
Vaccins
title Extended recombinant bacterial ghost system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T18%3A25%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extended%20recombinant%20bacterial%20ghost%20system&rft.jtitle=Journal%20of%20biotechnology&rft.au=Lubitz,%20W.&rft.date=1999-08-20&rft.volume=73&rft.issue=2&rft.spage=261&rft.epage=273&rft.pages=261-273&rft.issn=0168-1656&rft.eissn=1873-4863&rft.coden=JBITD4&rft_id=info:doi/10.1016/S0168-1656(99)00144-3&rft_dat=%3Cproquest_cross%3E70034197%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17343822&rft_id=info:pmid/10486935&rft_els_id=S0168165699001443&rfr_iscdi=true